Interferon News and Research

RSS

Study describes the dynamics of immune responses to triple COVID-19 vaccination

The effectiveness of the three-dose COVID-19 vaccination against SARS-CoV-2 and its variants has been described in detail in a recent study.

23 Sep 2022

Virology of the human monkeypox virus

A new review to be posted in the Virus Research journal aims to provide an overview of the recent advances reported concerning hMPXV virology.

21 Sep 2022

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

In a new study, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.

21 Sep 2022

Why fatigue from long COVID goes beyond simply feeling tired

In a recent study posted to the medRxiv* preprint server, researchers in the Netherlands examined the role of inflammatory genes, cytotoxic T-lymphocytes (CD8+ T cells), and pro-inflammatory cytokines in long-lasting severe fatigue experienced by a large number of coronavirus disease 2019 (COVID-19) patients.

21 Sep 2022

Research examines the roles of cytokines during SARS-CoV-2 infection in rhesus macaques

In a recent study posted to the bioRxiv* preprint server, researchers in the United States assessed the role of two cytokines, interferon-gamma (IFN-γ) and interleukin-10 (IL-10), in regulating immune cell responses and inflammation early during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in rhesus macaques.

18 Sep 2022

An improved COVID-19 vaccine shows promise against Omicron in experimental models

In a recent study published in the journal Science Translational Medicine, researchers in the United States designed a bivalent coronavirus disease 2019 (COVID-19) vaccine on the messenger ribonucleic acid (mRNA) platform.

18 Sep 2022

Gut microbiome associated with multiple sclerosis risk and disease development

An international research consortium led by UC San Francisco scientists has shown significant differences between the gut bacteria profiles of multiple sclerosis (MS) patients and healthy individuals, as well as between MS patients receiving different drug treatments.

15 Sep 2022

Bivalent recombinant vaccine protects against SARS-CoV-2 and influenza in animal models

In a new study, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.

15 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

The impact of the infant gut microbiome on vaccine efficacy

A new study reports the effect of the infant gut microbiome on vaccine efficacy.

13 Sep 2022

First report of a SARS-CoV-2 variant with an ORF7a deletion that dominated an outbreak

In a recent study posted to the medRxiv* preprint server, researchers in Australia determined whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta-ORF7aΔ17del [open reading frame 7a protein with 17-nucleotide (nt) frameshift-inducing deletion] variant has a fitness advantage over the Delta variant lacking the ORF7aΔ17del deletion (Delta-ORF7aintact) and/or the SARS-CoV-2 lineage (A.2.2).

12 Sep 2022

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* server, researchers in Singapore and the United States demonstrated that intranasal (I.N.) delivery of a mucosal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination triggered a superior T cell response compared to an equivalent dose of antigen delivered by the subcutaneous (S.C.) route.

12 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

In a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Interferon News and Research

Study describes the dynamics of immune responses to triple COVID-19 vaccination

Virology of the human monkeypox virus

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

Why fatigue from long COVID goes beyond simply feeling tired

Research examines the roles of cytokines during SARS-CoV-2 infection in rhesus macaques

An improved COVID-19 vaccine shows promise against Omicron in experimental models

Gut microbiome associated with multiple sclerosis risk and disease development

Bivalent recombinant vaccine protects against SARS-CoV-2 and influenza in animal models

Defensosomes versus COVID-19

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

The impact of the infant gut microbiome on vaccine efficacy

First report of a SARS-CoV-2 variant with an ORF7a deletion that dominated an outbreak

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Brain injury a common consequence of both COVID-19 and influenza

A direct side-by-side comparison of all available COVID-19 vaccines

Researchers review the epidemiology, clinical character, treatment, and prevention of human monkeypox

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News